Recode Therapeutics Raises Oversubscribed Series B Financing Round Of $80 Million
Round Type
Series B
Menlo ParkBiotechnologyHealthcareHealth CareDescription
ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the closing of an $80 million Series B financing round co-led by Pfizer Ventures and EcoR1 Capital. New investors include Sanofi Ventures, funds managed by Tekla Capital Management LLC, Superstring Capital and NS Investment. Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, L.P., and Osage University Partners (OUP). The proceeds from the Series B financing will be used to drive ReCode’s lead programs in primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) into human clinical studies, expand the pipeline of treatments for patients with life-limiting genetic respiratory diseases, advance its LNP platform for organ-specific delivery of RNA and gene correction therapies and increase internal manufacturing capabilities
Quick answer
ReCode Therapeutics raised an undisclosed amount in a Series B round, dated October 21, 2021. ReCode Therapeutics is based in Menlo Park, California, United States.
- How much did ReCode Therapeutics raise?
- ReCode Therapeutics raised an undisclosed amount in a Series B round on October 21, 2021.
- What does ReCode Therapeutics do?
- ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics.
- Where is ReCode Therapeutics based and how big is it?
- ReCode Therapeutics is based in Menlo Park, California, United States.
- Who are the decision-makers at ReCode Therapeutics?
- Fundz holds 1 contact at ReCode Therapeutics, including the Head of Clinical Operations | Rare Diseases. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who to call at ReCode Therapeutics, and when
A new round usually means ReCode Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day ReCode Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ReCode Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ReCode Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ReCode Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansReCode Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.